Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis-Reference-Cited by-同舟云学术

Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis

Published:2021-03 Issue:3 Volume:22 Page:402-410
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gharzai Laila A,Jiang Ralph,Wallington David,Jones Gavin,Birer Samuel,Jairath Neil,Jaworski Elizabeth M,McFarlane Matthew R,Mahal Brandon A,Nguyen Paul L,Sandler Howard,Morgan Todd M,Reichert Zachery R,Alumkal Joshi J,Mehra Rohit,Kishan Amar U,Fizazi Karim,Halabi Susan,Schaeffer Edward M,Feng Felix Y,Elliott David,Dess Robert T,Jackson William C,Schipper Matthew J,Spratt Daniel E

Funder

National Institutes of Health

Prostate Cancer Foundation

Publisher

Elsevier BV

Subject

Oncology

Reference18 articles.

1. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer;Xie;J Clin Oncol,2017

2. The validation of surrogate endpoints in meta-analyses of randomized experiments;Buyse;Biostatistics,2000

3. Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation;Xie;J Clin Oncol,2020

4. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration;Liberati;PLoS Med,2009

5. A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses;Xie;JNCI Cancer Spectr,2019

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Undetectable PSA predicts outcome after salvage radiotherapy for biochemical recurrence following radical prostatectomy;Radiotherapy and Oncology;2024-11

2. Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint;Pharmaceutical Statistics;2024-07-02

3. Instant Oncology: FLAME;Clinical Oncology;2024-05

4. Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review;European Urology Oncology;2024-05

5. SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer;BMC Cancer;2024-04-08